Eukaryotic initiation factors (eIFs) are a crucial group of proteins involved in the initiation phase of protein translation in eukaryotic cells. This process, known as translation initiation, marks the beginning of protein synthesis, and it plays a central role in regulating gene expression. eIFs orchestrate the assembly of ribosomes on messenger RNA (mRNA) and the recruitment of transfer RNA (tRNA) molecules bearing amino acids, enabling the synthesis of polypeptide chains. This intricate process is highly regulated and essential for proper cellular function. One of the key events in translation initiation is the formation of the eIF complex known as the eIF4F complex, which consists of eIF4E, eIF4A, and eIF4G. eIF4E binds to the mRNA cap structure, eIF4A serves as an RNA helicase, and eIF4G acts as a scaffold protein facilitating the interaction between various translation factors. This complex plays a pivotal role in mRNA recruitment to ribosomes, allowing efficient translation to occur. Additionally, eIF2 is another critical factor in translation initiation, responsible for delivering the initiator tRNA to the ribosome's P-site.
eIF inhibitors are a class of chemical compounds that target key components of the eIF signaling pathway, disrupting their normal functions and consequently impeding the initiation of protein translation. These inhibitors may act at various stages of translation initiation, including the inhibition of eIF4F complex formation, disruption of eIF2 function, or interference with RNA helicase activity. By interfering with these critical steps, eIF inhibitors can modulate the rate of protein synthesis, potentially leading to global changes in gene expression.
SEE ALSO...
Items 1 to 10 of 16 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Eeyarestatin I | 412960-54-4 | sc-358130B sc-358130 sc-358130A sc-358130C sc-358130D sc-358130E | 5 mg 10 mg 25 mg 50 mg 100 mg 500 mg | $114.00 $203.00 $354.00 $697.00 $1363.00 $5836.00 | 12 | |
Eeyarestatin I inhibits eIF2α dephosphorylation, leading to sustained phosphorylation and decreased protein synthesis. | ||||||
GSK 2606414 | 1337531-36-8 | sc-490182 sc-490182A | 5 mg 25 mg | $163.00 $572.00 | ||
GSK2606414 inhibits the activity of PERK, a kinase that phosphorylates eIF2α, reducing eIF2α phosphorylation levels. | ||||||
Sephin1 | 13098-73-2 | sc-507502 | 5 mg | $578.00 | ||
Sephin1 selectively inhibits the eIF2α phosphatase, GADD34, preventing eIF2α dephosphorylation and reducing translation. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin indirectly affects eIF2α by causing DNA damage, triggering the integrated stress response and eIF2α phosphorylation. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Etoposide causes DNA damage, which could lead to a cellular stress response, potentially diverting cellular resources from RNAi pathways and thus down-regulating eIF2C2. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
By acting as a pyrimidine analog, 5-Fluorouracil might disrupt nucleotide metabolism. This disruption could indirectly affect RNAi components by hampering RNA synthesis, leading to decreased eIF2C2 levels. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D hinders RNA synthesis by intercalating DNA. This can lead to a general down-regulation of RNA-derived processes, which might include a decrease in eIF2C2 levels. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
By inhibiting protein synthesis, Cycloheximide might halt the production of new eIF2C2 molecules, leading to a net decrease in eIF2C2 as existing proteins degrade. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
DNA damage from Doxorubicin may cause the cell to prioritize DNA repair over regular functions, potentially suppressing RNAi machinery and decreasing eIF2C2 levels. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Camptothecin's inhibition of topoisomerase I can cause DNA damage, which might lead to a reduced focus on RNAi processes and subsequent lower eIF2C2 expression. | ||||||